MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per

Bio-Techne Declares Dividend

2026/02/04 19:46
3 min read

MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2025. The quarterly dividend will be payable February 27, 2026, to all common shareholders of record on February 16, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio­-techne.com.

Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company’s actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company’s customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled “Risk Factors” in the Company’s annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

Contact:

David Clair, Vice President, Investor Relations

David.Clair@bio-techne.com

612-656-4416

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-declares-dividend-302678498.html

SOURCE Bio-Techne Corporation

Market Opportunity
BIO Protocol Logo
BIO Protocol Price(BIO)
$0.02464
$0.02464$0.02464
+1.56%
USD
BIO Protocol (BIO) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Chorus One and MEV Zone Team Up to Boost Avalanche Staking Rewards

Chorus One and MEV Zone Team Up to Boost Avalanche Staking Rewards

The post Chorus One and MEV Zone Team Up to Boost Avalanche Staking Rewards appeared on BitcoinEthereumNews.com. Through the partnership with MEV Zone, Chorus One users will earn extra yield automatically. The Chorus One Avalanche node has a total stake of over 1.7 million, valued at around $55 million. This collaboration will introduce MEV Zone to both public nodes and Validator-as-a-Service. The Avalanche network stands to benefit from fairer and more efficient markets due to enhanced transparency. Chorus One, a highly decorated institutional-grade staking provider, has inked a strategic partnership with MEV Zone to enhance yield generation on the Avalanche (AVAX) network. The Chorus One partnered with MEV Zone to increase the AVAX staking yields, while simultaneously contributing to the general growth of the Avalanche network. “At Chorus One, we see this as an important step in our ongoing journey to provide robust infrastructure and innovative yield strategies for our partners and clients,” the announcement noted.  Why Did Chorus One Partner With MEV Zone? The Chorus One platform has grown to a top-tier institutional-grade staking ecosystem, with more than 40 blockchains, since 2018. In a bid to evolve with the needs of crypto investors and the supported blockchains, Chorus One has inked several strategic partnerships in the recent past, including MEV Zone. In the recent past, MEV Zone has specialized in addressing the Maximal Extractable Value (MEV) challenges on the Avalanche network. The MEV Zone will help Chorus One’s AVAX node validator to use Proposer-Builder Separation (PBS). As such, Chorus One’s AVAX node will seamlessly select certain transactions that are more profitable when making blocks. For instance, MEV Zone will help Chorus One’s AVAX node validator to capture arbitrage and liquidation transactions more often since they are more profitable.  How will Chorus One’s AVAX Stakers Benefit Via This Partnership? The Chorus One AVAX node has grown over the years to more than 1.77 million coins staked, valued…
Share
BitcoinEthereumNews2025/09/18 03:19
Strategy CEO: The company will issue more perpetual preferred stock to alleviate investor concerns about the share price.

Strategy CEO: The company will issue more perpetual preferred stock to alleviate investor concerns about the share price.

PANews reported on February 12th, citing Bloomberg, that Strategy CEO Phong Le stated in an interview that the company will issue more perpetual preferred stock
Share
PANews2026/02/12 08:13
USD/MYR Exchange Rate Faces Critical Test: Range-Bound Trading Near Multi-Year Lows Sparks Market Watch

USD/MYR Exchange Rate Faces Critical Test: Range-Bound Trading Near Multi-Year Lows Sparks Market Watch

BitcoinWorld USD/MYR Exchange Rate Faces Critical Test: Range-Bound Trading Near Multi-Year Lows Sparks Market Watch KUALA LUMPUR, March 2025 – The USD/MYR currency
Share
bitcoinworld2026/02/12 08:35